MRVI — Maravai LifeSciences Holdings, Inc.

Summary of Maravai LifeSciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 Revenue: $49.9 million, an 18% increase year-over-year when excluding $14.3 million from high-volume COVID GMP CleanCap sales in Q4 2024.
• Full Year Revenue: $185.7 million, exceeding guidance by $700,000.
• GAAP Net Loss: $63 million for Q4, including a $25.8 million noncash intangible asset impairment charge and $12.1 million in restructuring charges. Full year net loss was $230.8 million, improved from $259.6 million in 2024.
• Adjusted EBITDA: Positive $536,000 in Q4, a significant improvement from negative $1.1 million in Q4 2024. Full year adjusted EBITDA was negative $31.2 million, an improvement from negative $35.9 million in 2024.
• Cash Position: Ended the year with $216.9 million in cash and $294.2 million in long-term debt. A voluntary $50 million debt repayment was made in Q1 2026.

2. Strategic Updates and Business Highlights:

• The company restructured its reportable segments, now named TriLink and Cygnus, to align with branding.
• TriLink saw a 25% increase in base revenue year-over-year, driven by GMP consumables and CDMO services.
• Cygnus revenue grew 4% year-over-year, with strong demand for HCP kits.
• The launch of the mRNAbuilder platform is enhancing customer engagement and driving demand for GMP-grade supplies.
• The ModTail technology has gained traction, generating over $0.5 million in 2025 and exceeding that in 2026 year-to-date bookings.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected total revenue of $200 million to $210 million, reflecting 8% to 13% growth over 2025.
• Adjusted EBITDA Guidance: Projected at $18 million to $20 million, a significant improvement from 2025.
• Anticipated gross margin expansion of approximately 1,200 basis points due to restructuring and product mix improvements.
• TriLink is expected to grow in low double digits, while Cygnus is projected to grow in low to mid-single digits.

4. Bad News, Challenges, or Points of Concern:

• Despite improvements, the company reported a substantial GAAP net loss and ongoing restructuring costs, indicating challenges in achieving profitability.
• The previous year’s high-volume COVID-related sales are no longer expected, which could impact revenue stability.
• The company faces competitive pressures in the mRNA and gene therapy markets, with ongoing scrutiny from regulatory bodies affecting certain segments.

5. Notable Q&A Insights:

• Management expressed confidence in strong order volumes for 2026, indicating that orders are tracking ahead of revenue guidance.
• The company highlighted that the growth in GMP consumables is broad-based across various customers, not reliant on a few key accounts.
• There was discussion about the impact of new FDA guidance, with management noting limited exposure to vaccine-related policies.
• The Q&A revealed a focus on the potential for MockV and other new products to drive growth beyond current expectations, with a long-term view on margins improving as revenue increases.

Overall, Maravai LifeSciences is showing signs of recovery and growth potential, driven by strategic initiatives and operational improvements, despite facing challenges related to past COVID-related sales and ongoing net losses.